Sertindole for the treatment of schizophrenia

Bibliography

• Jablensky A, Sartorius, Eruberg G, Schizophrenia; manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med Monograph Suppl 1992;20:1-97
   PubMedGoogle Scholar
• Cannon M, Jones P. Schizophrenia. J Neurol Neurosurg Psychiatr 1996;20:604-13
   Google Scholar
• Nuechterlein KH, Dawson ME. A heuristic vulnerability/stress model of schizophrenic episodes. Schizophr Bull 1984;10:300-12
   PubMed Web of Science ®Google Scholar
• Hafner H, Maurer K, Loffler W, Modeling the early course of schizophrenia. Schizophr Bull 2003;29:325-40
   PubMed Web of Science ®Google Scholar
• Knoll JL, Garver DL, Ramberg JE, Heterogeneity of the psychoses: is there a neurogenerative psychosis? Schizophr Bull 1988;24:365-79
   Web of Science ®Google Scholar
• Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry 1999;46:729-39
   PubMed Web of Science ®Google Scholar
• Weinberger DR, Gallhofer S. Cognitive function in schizophrenia. Int Clin Psychopharmacol 1997;12:S29-36
   Web of Science ®Google Scholar
• Addington J, Addington D. Neurocognitive and social functioning in schizophrenia. Schizophr Bull 1999;25:173-82
   PubMed Web of Science ®Google Scholar
• Brown S, Inskip H, Barraclough B. Courses of the excess mortality of schizophrenia. Br J Psychiatry 2000;177:212-17
   PubMed Web of Science ®Google Scholar
• Davies LM, Drummond MF. Economics and schizophrenia: the red cost. Br J Psychiatry 1994;25(Suppl):18-21
   Google Scholar
• Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-64
   PubMed Web of Science ®Google Scholar
• Geddes J, Freemantle N, Harrison P, ; for the National Schizophrenia Guideline Development Group. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-6
   PubMed Web of Science ®Google Scholar
• Leucht S, Corves C, Arbter D, Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31-41
   PubMed Web of Science ®Google Scholar
• Tandon R, Belmaker RH, Gattaz WF, World Psychiatric Association Pharmacopsychiatry section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 2008;100:20-38
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Kreyenbuhl J, Kelly DL, The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010;36:71-93
   PubMed Web of Science ®Google Scholar
• Perquin L, Steinert T. A review of the efficacy, tolerability and safety of sertindole in clinical trials. CNS Drugs 2004;18(Suppl 2):19-30
   PubMedGoogle Scholar
• Cincotta SL, Rodefer JS. Emerging role of sertindole in the management of schizophrenia. Neuropsychiatr Dis Treat 2010;6:429-41
   PubMed Web of Science ®Google Scholar
• Murdoch D, Keating GM. Sertindole. A review of its use in schizophrenia. CNS Drugs 2006;20:233-55
   PubMed Web of Science ®Google Scholar
• Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, ‘just the facts’ 5. Treatment and prevention. Past, present, and future. Schizophr Res 2010;122:1-23
   PubMed Web of Science ®Google Scholar
• Davis JM, Leucht S. Has research informed us on the practical drug treatment of schizophrenia? Schizophr Bull 2008;34:403-5
   PubMed Web of Science ®Google Scholar
• Foussias G, Remington G. Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making. Can J Psychiatry 2010;55:117-25
   PubMed Web of Science ®Google Scholar
• Zimbroff DL, Kane JM, Tamminga CA, Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997;154:782-91
   PubMed Web of Science ®Google Scholar
• Chiodo LA, Bunney BS. Possible mechanisms by which repeated clozapine administration differentially affect the activity of two subpopulations of midbrain dopamine neurons. J Neurosci 1985;5:2539-44
   PubMed Web of Science ®Google Scholar
• Thomas SHL, Drici MD, Hall GC, Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). Acta Psychiatr Scand 2010;122:345-55
   PubMed Web of Science ®Google Scholar
• Tamminga CA, Mack RJ, Granneman R, Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety. Int Clin Psychopharmacology 1997;12(Suppl 1):S29-35
   Google Scholar
• Hale AS. A review of the safety and tolerability of sertindole. Int Clin Psychopharmacol 1998;13(Suppl 3):S65-70
   Google Scholar
• Kasper S. Sertindole: safety and tolerability profile. Int J Psychiatry Clin Pract 2002;6(Suppl 1):S27-32
   PubMedGoogle Scholar
• Kane JM, Tamminga CA. Sertindole (Serdolect): preclinical and clinical findings of a new atypical antipsychotic. Expert Opin Invest Drugs 1997;6:1729-41
   PubMedGoogle Scholar
• Muscatello MRA, Bruno A, Pandolfo GL, Emerging treatments in the management of schizophrenia. Focus on sertindole. Drug Des Dev Ther 2010;4:187-201
   PubMed Web of Science ®Google Scholar
• Arnt J, Skarsfeldt T. Do novel antipsychotic have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998;18:63-101
   PubMed Web of Science ®Google Scholar
• Sanchez C, Arnt J, Dragsted N, Neurochemical and in vivo parmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Dev Res 1991;22:239-50
   Web of Science ®Google Scholar
• Hyttel J, Nielsen JP, Nowak G. The acute affect of sertindole on brain 5HT2, D2 and alpha1 receptors (ex vivo radioreceptor binding studies). J Neural Trans 1992;89:61-9
   PubMed Web of Science ®Google Scholar
• Skarsfeldt J. Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurons in rats: acute and repeated treatment. Synapse 1992;10:25-32
   PubMed Web of Science ®Google Scholar
• Hietala J, Kuoppamaki M, Majasuo H, Sertindole is a serotonin 5HT2c inverse agonist and decrease agonist but not antagonist binding to 5HT2c receptors after chronic treatment. Psychopharmacology 2001;157:180-7
   PubMed Web of Science ®Google Scholar
• Mork A, Witten LM, Arnt J. Effect of sertindole on extracellular dopamine, acetylcholine, and glutamate in the medial prefrontal cortex of conscious rats: a comparison with risperidone and exploration of mechanisms involved. Psychopharmacology 2009;206:39-49
   PubMed Web of Science ®Google Scholar
• Petit-Taboue MC, Landeau B, Barre L, Parametric PET imaging of 5HT2 A receptor distribution with 18 F-setoperone in the normal human cortex. J Nucl Med 1999;40:25-32
   PubMed Web of Science ®Google Scholar
• Nyberg S, Olsson H, Nilsson U, Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole. Psychopharmacology 2002;162:37-41
   PubMed Web of Science ®Google Scholar
• Pilowsky LS, O'Connell P, Davies N, In vivo effects on striatal dopamine D2 receptor binding by the novel atypical antipsychotic drug sertindole: a 123 I - IBZM single photon emission tomography (SPET) study. Psychopharmacology (Berl) 1997;130:152-8
   PubMed Web of Science ®Google Scholar
• Kasper S, Tauscher J, Kufferle B, Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol: a 123 I - IBZM SPECT study. Psychopharmacology (Berl) 1998;136:367-73
   PubMed Web of Science ®Google Scholar
• Buchsbaum MS, Haznedar M, Newmark RE, FDG and MRI imaging of the effects of sertindole and haloperidol in the prefrontal lobe in schizophrenia. Schizophr Res 2009;114:161-74
   PubMed Web of Science ®Google Scholar
• Skarsfeldt T. Differential effect of antipsychotics on place navigation of rats in the Morris water maze. A comparative study between novel and reference antipsychotics. Psychopharmacology 1996;124:126-33
   PubMed Web of Science ®Google Scholar
• Didriksen M, Kreilgaard M, Arnt J. Sertindole, in contrast to clozapine and olanzapine, does not disrupt water maze performance after acute or chronic treatment. Eur J Pharmacol 2006;542:108-15
   PubMed Web of Science ®Google Scholar
• Didriksen M. Effects of antipsychotics on cognitive behaviour in rats using the delayed non-match position paradigm. Eur J Pharmacol 1995;281:241-50
   PubMed Web of Science ®Google Scholar
• Rodefer JS, Nguyen TN, Karlsson JJ, Arnt J. Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5HT6 receptor antagonist: comparison among antipsychotics. Neuropsychopharmacol 2008;33:2657-66
   PubMed Web of Science ®Google Scholar
• Rampe D, Murawksy MK, Grau J, Lewis EW. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp Ther 1998;262:788-93
   Google Scholar
• Haverkamp W, Eckardt L, Matz J. Sertindole: cardiac electrophysiological profile. Int J Psychiatry Clin Pract 2002;6(Suppl 1):S11-20
   PubMedGoogle Scholar
• Lindstrom E, Farde L, Eberhard J, QTc interval prolongation and antipsychotic drug treatments: focus on sertindole. Int J Neurospychopharmacol 2005;8:615-29
   PubMed Web of Science ®Google Scholar
• Eckardt L, Breithardt G, Haverkamp W. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointe: low torsado-genic potential despite QT prolongation. J Pharmacol Exp Ther 2002;300:64-71
   PubMed Web of Science ®Google Scholar
• Thomsen MB, Volders PGA, Stengl M, Electrophysiological safety of sertindole in dogs with normal and remodeled hearts. J Pharmacol Exp Ther 2003;307:776-84
   PubMed Web of Science ®Google Scholar
• Titier K, Canal M, Deridet E, Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice. Toxicol Appl Pharmacol 2004;199:52-60
   PubMed Web of Science ®Google Scholar
• Wong SL, Linnen P, Mack R, Effects of food, antacid and dosage form on the pharmacokinetics and relative bioavailability of sertindole in healthy volunteers. Biopharm Drug Dispos 1997;18:533-41
   PubMed Web of Science ®Google Scholar
• Wong SL, Cao G, Mack RJ, Pharmacokinetics of sertindole in healthy young and elderly male and female subjects. Clin Pharmacol Ther 1997;18:533-41
   Google Scholar
• Wong SL, Menacherry S, Mulford D, Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function. Eur J Clin Pharmacol 1997;52:223-7
   PubMed Web of Science ®Google Scholar
• Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics (PtI): pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother 1999;33:73-85
   PubMed Web of Science ®Google Scholar
• Wong SL, Granneman GR. Modeling of sertindole pharmacokinetic disposition in healthy volunteers in short-term dose-escalation studies. J Pharm Sci 1998;87:1629-31
   PubMed Web of Science ®Google Scholar
• Ouellet D, Cao G, Staser J, Population pharmacokinetics of sertindole in patients with schizophrenia [abstract n PII-50]. Presented at the 99th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics 5 – 8 March 1997; San Diego, CA, USA
   Google Scholar
• H. Lundbeck A/S. Sertindole: summary of product characteristics. Copenhagen: H. Lundbeck A/S, 2005
   Google Scholar
• Data on file, H. Lundbeck A/S, 2006
   Google Scholar
• McEvoy J, Borison R, Small J, The efficacy and tolerability of sertindole in schizophrenic patients: a pilot, double-blind, placebo-controlled, dose ranging study [abstract]. Schizophr Res 1993;9:244
   Google Scholar
• van Kammen DP, Mc Evoy JP, Targum SD, A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 1996;124:168-75
   PubMed Web of Science ®Google Scholar
• Hale A, Azorin JM, Kasper S, Sertindole improves both the positive and negative symptoms of schizophrenia: results of a phase III trial. Int J Psychiatr Clin Pract 2000;4:55-62
   PubMed Web of Science ®Google Scholar
• Daniel DG, Wozniak P, Mack RJ, Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. Psychopharmacol Bull 1998;34:61-9
   PubMed Web of Science ®Google Scholar
• Azorin JM, Strub N, Loft H. A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. Int J Psychopharmacol 2006;21:49-56
   PubMed Web of Science ®Google Scholar
• Kane JM, Potkin SG, Daniel DG, Buckley P. A double-bind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. J Clin Psychiatry 2010 Jul 27 [Epub ahead of print]
   Google Scholar
• Leucht S, Arbter D, Engel RR, How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 2009;14:429-47
   PubMed Web of Science ®Google Scholar
• Komossa K, Rummel-Kluge C, Hunger H, Sertindole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009;15:CD006752
   Google Scholar
• Leucht S, Komossa K, Rummel-Kluge C, A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009;166:152-63
   PubMed Web of Science ®Google Scholar
• Gallhofer B, Jaanson P, Mittoux A, Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol. Pharmacopsychiatry 2007;40:275-86
   PubMed Web of Science ®Google Scholar
• Chang RJ, Swann AC, Becker LA, A one year, controlled cost-effectiveness study comparing sertindole and haloperidol in stable schizophrenic patients. Poster presented at the 7th World Congress of Biological Psychiatry July 1 – 6 2001; Berlin, Germany
   Google Scholar
• Azorin JM, Murteira S, Hansen K, Toumi M. Evaluation of patients on sertindole treatment after failure of other antipsychotics: a retrospective analysis. BMC Psychiatry 2008;8:8-16
   PubMedGoogle Scholar
• Moore N. Higher cardiovascular mortality with sertindole in ADROIT: a signal not confirmed. Int J Psych Clin Pract 2002;6(Suppl 1):S53-9
   PubMedGoogle Scholar
• Wilton LV, Heeley EL, Pickering RM, Shakir SA. Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine. J Psychopharmacol 2001;15:120-6
   PubMed Web of Science ®Google Scholar
• Muldoon C, Cochran J. Mortality rates in three comparative cohorts of patients who received sertindole, olanzapine or risperidone: a hospital-based, retrospective study. J Outcomes Res 2006;10:47-55
   Google Scholar
• Peuskens J, Moore N, Azorin JM, The European sertindole safety and exposure survey: a follow-up study of 8 600 patients. Pharmacoepidemiol Drug Saf 2007;16:804-11
   PubMed Web of Science ®Google Scholar
• Kasper S, Moller HJ, Hale A. The European Post-Marketing Observational Sertindole Study: an investigation of the safety of antipsychotic drug treatment. Eur Arch Psychiatry Clin Neurosci 2010;260:59-68
   PubMed Web of Science ®Google Scholar
• Sturkenboom MCJM, Picelli G, Moore N. Mortality during use of sertindole and other anti-psychotics in the Netherlands and Belgium [abstract 273]. Pharmacoepidemiol Drug Saf 2001;10:S1-164
   PubMedGoogle Scholar
• Lancon C, Toumi M, Sapin C, Hansen K. The Sertindole Safety Survey: a retrospective analysis under a named patient use programme in Europe. BMC Psychiatry 2008;8:57
   PubMed Web of Science ®Google Scholar
• Ray WA, Chung CP, Murray KT, Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360:225-35
   PubMed Web of Science ®Google Scholar
• Ucok A, Gaebel W. Side effects of atypical antipsychotics: a brief overview. World Psychiatry 2008;7:58-62
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
   PubMed Web of Science ®Google Scholar
• Strom BL, Faich GA, Reynolds RF, The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): design and baseline subject characteristics. J Clin Psychiatry 2008;69:114-21
   PubMed Web of Science ®Google Scholar
• Eng SM, Strom BL, Faich GA, Comparative mortality associated with ziprasidone versus olanzapine in real world use: the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Schizophr Res 2008;98(Suppl 1):160-1
   Google Scholar
• Kasper S, Hale A, Azorin JM, Moller HJ. Benefit–risk evaluation of olanzapine risperidone and sertindole in the treatment of schizophrenia. Eur Arch Psychiatry Clin Neurosci 1999;249(Suppl 2):2-14
   PubMedGoogle Scholar
• Toumi M, De Jonghe D. Assesment of potential risk of occurrence of torsades de pointe in sertindole-treated patients, and identification of potential risk factors for QTc interval prolongation. H Lundbeck A/S, internal report, 1998
   Google Scholar
• Nielsen J, Andersen MP, Graff C, The effect of sertindole on QTD and TPTE. Acta Psychiatr Scand 2010;121:385-8
   PubMed Web of Science ®Google Scholar
• Nielsen J, Graff C, Hardahl T, Sertindole causes distinct electrocardiographic T-wave morphology changes. Eur Neuropsychopharmacol 2009;19:702-7
   PubMed Web of Science ®Google Scholar
• Crocq MA, Naber D, Lader MH, Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone. Eur Neuropsychopharmacol 2010;20:829-38
   PubMed Web of Science ®Google Scholar
• Lewis R, Bagnall AM, Leitner M. Sertindole for schizophrenia. Cochrane Database Syst Rev 2005;3:CD001715
   Google Scholar
• Perquin LN. Treatment with the new antipsychotic sertindole for late-occurring undesirable movement effects. Int Clin Psychopharmacol 2005;20:335-8
   PubMed Web of Science ®Google Scholar
• De Hert M, Mittoux A, He Y, Peuskens J. A head-to-head comparison of sertindole and risperidone on metabolic parameters. Schizophr Res 2010;123:276-7
   PubMed Web of Science ®Google Scholar
• De Hert M, Mittoux A, He Y, Peuskens J. Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone. Eur Arch Psychiatry Clin Neurosci 2010. [Epub ahead of print]
   Google Scholar
• Launois R, Graf von der Schulenburg, Knapp M, Toumi M. Cost-effectiveness of sertindole versus olanzapine or haloperidol: a comprehensive model. Int J Psychiatry Clin Pract 1998;2(Suppl 2):S79-86
   PubMedGoogle Scholar
• Dordzinski WJ, Paulik D, Nogas G. Cost-utility and budget impact of sertindole in the treatment of schizophrenia in Poland. ISPOR 11th Annual European Congress, 8 – 11 November 2008; Athens, Greece
   Google Scholar
• Hansen K, Launois R, Sapin C. Pharmacoeconomic positioning of sertindole among atypical antipsychotics in the management of schizophrenia in Turkey. International Health Economics Association (iHEA) 2007, 6th World Congress: Explorations in Health Economics Paper
   Google Scholar
• Wirshing DA, Meyer JM. Obesity in patients with schizophrenia. In: Meyer JM, Nasrallah HA, editors, Medical illness and schizophrenia. American Psychiatric Publishing, Washington, DC; 2003. p. 35-51
   Google Scholar
• Henderson DC, Powers Ettinger E. Glucose intolerance and diabetes in schizophrenia. In: Meyer JM, Nasrallah HA, editors, Medical illness and schizophrenia. American Psychiatric Publishing, Washington DC; 2003. p. 99-114
   Google Scholar
• Moore N, Hall G, Sturkenboom M, Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Saf 2003;12:271-81
   PubMed Web of Science ®Google Scholar
• Schuck P, van den Ameele M, Jaanson P. Case histories illustrating the utility of sertindole in clinical practice. CNS Drugs 2004;18(Suppl 2):31-40
   PubMedGoogle Scholar
• Lieberman JA, Tollefson GD, Charles C, Antipsychotic drug effects on brain morphology in first episode psychosis. Arch Gen Psychiatry 2005;62:361-70
   PubMed Web of Science ®Google Scholar